|Title of Invention||
NOVEL SUBSTITUTED THIAZOLYL ACETIC ACID
|Abstract||The present invention provides novel substituted thiazolyl acetic acid of general formula (I) wherein, R<sub>1</sub> represents H, trityl, CH<sub>3</sub>, CR<sub>a</sub> R<sub>b</sub> COOR<sub>2</sub> (R<sub>a</sub> and R<sub>b</sub>independently of one another represents hydrogen or methyl, R<sub>2</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl).|
NEW THIOESTER DERIVATIVES OF THIAZOLYL ACETIC ACID
Field of the invention
The present invention relates to novel thioester derivatives of thiazolyl acetic acid of general formula (I), useful as an intermediate for the preparation of cephalosporin antibiotics having general formula (II). In addition, the present invention also relates to a process for the preparation of thioester derivatives. The present invention also provides for a process for the preparation of cephalosporin antibiotics using said thioester derivatives.
wherein, Ri represents H, trityl, CH3, CRaRbC00R2
(Ra and Br independently of one another represent hydrogen or
methyl and R2 represents H or C1-C4 alkyl)
R3 is CH3 -CH=CH2, -CH2OCH3, -CH2OCOCH3
R4 is H or a sah or a carboxylic protecting group or an inner salt
Background of the Invention
Use of acid chlorides, anhydrides, esters, amide etc. is reported in the chemical literature for activation of carboxylic acid of formula (IV).
Activation in the form of acid chloride required protection and deprotection of NH’ group.
Activation of acid (IV) is reported by SO2CI2/DMF in US patent 5,856,502 and SOCI2/DMF in US patent 5,037,988. These processes suffer the limitation of using harmful and pungent smelling chemicals like SOCI2, SO2CI2 along with solvents like benzene, toluene, etc. and involving stringent conditions for carrying out the reactions on commercial scale.
In US patent Nos. 4,576,749 and 4,548,748, the acid of formula (IV) has also been
activated by reacting with 1-hydroxybenzotriazole (HOBT) or 2-mercaptobenzothiazole
(MBT) in the presence of dicyclohexylcarbodiimide (DCC) to produce reactive ester of the
acid (IV) which is then reacted with cephem moiety to prepare cephalosporin antibiotics,
but the processes are time consuming accompanied with low yields, hence, not suitable.
US patent No. 4767852 discloses a process for production of ciphers by acylating 7-
amino-3-cephem-4-carboxylic acid with 2-mercaptobenzothiazolyl-(Z)-2-(2"aminothiazol-
4-yl)-2-methoxyimmoacetate (MAEM). Similarly, US Pat.No.5026843 (1991) disclosed a
process for preparing ceftriaxone disodium hemiheptahydrate by acylation of 7-amino-3-
carboxylic acid (7-ACT) by using MAEM as acylating agents in good yield and quality. Thus MAEM has become the standard acylating agent for the preparation of cephalosporins antibiotics having an examine group and a 2-aminothiazolyl group in 7-position of cephem compounds.
However, the synthesis of MAEM from acid (III) and 2,2'-dithio-bis-benzothiazole involves use of costly condensing agent triphenylphosphine (TPP). Moreover, during condensation of MAEM with 7-aminO'3'Cephem-4-carboxylic acid compound (III), a toxic compound 2-mercaptobenzothiazole (MBT) is also produced as a byproduct [Chemical Abstracts, 111, p. 19243 (1989)], which is difficult to remove. Thus, it is evident that the procedures described in the prior art for the preparation of these cephalosporin antibiotics are complex, involving protection, deprotection and also associated with generation of toxic byproduct. Hence, there is a need to develop new acylating agents which are capable of transferring the 2-aminothiazolyl moiety to cephem compounds of formula (III) in good yield, without producing this toxic byproduct. On the similar lines, a new thioester was reported by D.G.Walker, Tet. Lett. 1990, 31,64(S1 to
acylate the cephem moiety to get caffeine sulfate but yields obtained by using this thioester were in the range of 54-73% which cannot be considered as good yield to operate a process at commercial scale. The same thioester is exploited in US patent No. 5869649 for making three more important cephalosporin antibiotics.
In the CO pending application US Application No. 09/754,302, the Applicant has disclosed another novel thioester derivatives of thiazole acetic acid and its use in the synthesis of various cephalosporin antibiotics. In continuation of search for more such derivatives, the Applicant has observed that the title compound (I) works equally well and also has the similar advantages as described in the aforementioned US application.
Objectives of the Invention
The primary objective of this invention is to provide novel thioester derivatives of thiazolyl
acetic acid of formula (I) used for the preparation of cephalosporin antibiotics of formula
Another objective of this invention is to prepare new thioester derivatives of thiazolyl
acetic acid of formula (I) which is better than the earlier reactive derivatives and also
suitable for being used in the manufacture of cephalosporin antibiotics.
Yet another objective of the present invention is to provide a process for the synthesis of
thioester derivatives of formula (I) from thiazolyl acetic acid of formula (IV) and 1,2,5,6
tetrahydro-2-methyl-5, 6- dipxo-l,2,4-triazin-3-thiol (VI).
Still another objective of the present invention is to provide a process for the preparation of
cephalosporin antibiotics of general formula (II) at low temperature, which will be simple
and cost effective.
Yet another objective of the present invention is to produce cephalosporin antibiotics
having high purity and free from toxic byproducts.
One more objective of the present invention is to provide a process for the preparation of
cephalosporin antibiotics of general formula (II) from said novel thioester derivatives.
Summary of the Invention
The present invention provides a new thioester derivatives of thiazolyl acetic acid of
formula (I) and also provides a method by which the said thioester derivatives can be
prepared by reacting thiazolyl acetic acid of general formula (IV) with the commercially
available 1,2,5,6 tetrahydro-2-methyl-5,6 dioxo-l,2,4-triazin-3-thiol (VI) using Vilsmeier
reagent (V) as a condensing agent. (Ber. 60B, 119 (1927). The thioester derivatives thus
obtained are reacted with 7-amino-cephem carboxylic acids of general formula (III) to
produce cephalosporin antibiotic compounds of general formula (II) as described above.
The cephalosporin antibiotics obtained are of high purity (95-99%). The method is
workable on commercial scale without necessitating the protection of the amino group of
the acylating agents, and avoiding the generation of the toxic product 2-
Detailed Description of the Invention
The present invention provides novel derivatives of thiazolyl acetic acid represented by
(I) wherein, Ri represents H, trityl, CH3, CRaRbCOORa (Ra and Rb
independently of one another represents hydrogen or methyl, R2 is
hydrogen or C1-C4 alkyl) An embodiment of the present invention provides a process for the preparation of a new thioester of formula (I) as mentioned above. The said process comprising the step of condensing thiazolylacetic acid represented by formula (IV)
wherein, Ri represents H, trityl, CH3, CRaRbCOORa (Ra and Rb independently of one another represents hydrogen or methyl and R2 represents H or C1-C4 alkyl). with 1,2,5,6 tetrahdro-2"methyl-5,6 dioxo-l,2,4-triazin-3-thiol of formula (VI)
to obtain the thioesters of formula (I).
The thioester of general Formula (I) thus obtained is reacted with 7-amino cephem
carboxylic acids of general formula (III) in an organic solvent in presence of an organic
base to obtain cephalosporin antibiotics of general formula (II).
The reactions scheme is shown here below:
wherein, in formula (I), Ri represents H, trityl, CH3, CRaRbC00R2 (Ra and Rb independently of one another represents hydrogen or methyl and R2 represents H or C1-C4 alkyl), in formula (III) R3 represents -CHs, -CH’CH., -CH2OCH3, -CH2OCOCH3,
Another embodiment of the present invention provides a method by which cephalosporin antibiotics are obtained in high purity and excellent yield without the necessity for protecting the amino group of the acylating agents and avoiding the production of toxic byproduct namely 2-mercaptobenzothiazole (MBT).
In one another embodiment of the present invention, the substituent R3 in cephem compound (II) and (III) represents methyl, acetyloxymethyl, methoxymethyl, vinyl, pyridylmethyl, propenyl, 2,5-dihydro-6-hydroxy-2-methyU5-oxo-l,2,44riazine-3-thiol, furanyl-2-carbonyIthiol. In general, R3 represents -Chan-X wherein X is a residue of any organic or inorganic nucleophilic compound, e.g,, halogen, hydroxy, cyano, mercapto, azido, amino, etc. Furthermore, X may preferably represent residue of any 5 or 6 membered heterocyclic thiol.
In yet another embodiment of the present invention, the substituent R4 represents hydrogen, salt, a standard carboxylic protecting group, or a inner salt. Especially it is termed as carboxylate ion when R3 is pyridylmethyl, which ultimately explains the neutrality of the molecules.
Another embodiment of the invention provides the use of Vilsmeier reagent of formula (V) as condensing agent.
Still another embodiment of the invention provides acylation of (III) (when R5 is H) is
performed in presence of a water miscible solvent like tetrahydrofuran (THF), acetonitrile,
acetone, dioxane, N,N-dimethylfonnamide etc. but the preferable solvents are THF and
In an embodiment of the present invention, acylation of (III) (when R5 is trimethylsilyl) is
carried out in aprotic organic solvents like halogenated hydrocarbons, toluene, acetonitrile,
alkyl ethers etc., but preferable solvent is acetonitrile and dichloromethane. More suitable
salivating agents used for the reaction are hexamethyldisalazane, bis (trimethyl)
silylacetamide and trimethylsilyl chloride or a mixture thereof.
In yet another embodiment of the present invention, the organic base may be selected from
triethylamine, diethylamine, tributylamine, N-alkylpipridine, N-alkylanilines, 1,8-
diazabicyclo[5.4.2]undec-7-ene, l,5-diazabicyclo[4.3,0]non-5-ene, N-methylmorpholine,
l,4-diazabicyclo[2.2.2]octane, 4-dimethylamino pyridine and mixtures thereof.
The conceptual utility of this new thioesters of 1,2,5,6 tetrahdro-2-methyl-5,6 dioxo-1,2,4-
triazin-3-thiol of general formula (VI) is also tried in various coupling reactions of
carboxylic acids and amines. Most of amide formation reactions have shown good results.
L-alanine, 5'methylisoxazole-4-carboxylic acid, 2-thienylacetic acid, etc. are some of the
compounds, which have been activated by above mentioned thiol of formula (VI). Some
of the results are summarized in the following table.
Many other beneficial results are obtained by applying disclosed invention in a different
manner or by modifying the invention within the scope of disclosure. However, since the
major characteristic feature of the present invention resides in the use of novel reactive
thioester derivatives of thiazolyl acetic acid of general formula (I) in preparing the
cephalosporin antibiotics, the technical scope of the present invention should not be limited
to the following examples.
The invention is illustrated with the following examples, which should not be construed as
limiting the scope of the invention.
Synthesis of 1,2,5,6 tetrahydro-2-methy’3- thio-5,6 dioxo-l,2,4-triazine-(Z)-2"(2-
aminothiazoI-4-yl)-2-methoxyimino acetate (I).
To the cold Dimethylformamide (DMF), (50g), phosphorousoxychloride (POCI3) (84g)
was added slowly in 30 nun and stirred at 0-10 ‘C. Acetonitrile 1.0 lit was added and
reaction mass cooled further to -20 to -45’C and (ZH2-aminothiazoU4-yl)methoxyimino '
acetic acid (lOOg) was added and stirred for 30 min. 1,2,5,6 tetrahydro-2-methyU 5,6
dio\o-l,2,4-triazine'3- thiol ( 96 g) followed by pyridine (198 g) was added . The reaction
mixture was stirred for 30 min. After the reaction was complete, distilled water 1800ml
was added to the reaction solution and the mixture was stirred for 10 min. The product was
filtered, washed with water (1.0 lit) and acetone (1.0 lit) Dried to obtain 146g (yield 86 %)
of the title compound as light yellow solid.
Melting point : 187’C
'HNMR (DMS0-d6) : 5 3 J8 (3H,s,N-CH3), 3.96 (3H,s,N-OCH3), 7,4 (lH,s, thiazole ring
proton), 7.25(2H,bs,NH2), 13.9 (IH, s,OH) '‘CNMR(DMSOd,):645.6,64.0J12.3,141.0,144.6,146.5,149.3,159.5,169.8,174.4. Mass spectra : M’ peak = 343
Example - II 7-[[(Z)-2-(2-Aminothia2ol-4-yI)2-methoxyimino]acetamido]-3-[[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-l,2,4-triazin-3-yl)thio]methyl]-3-cephem-4-carboxylicacid disodium hemiheptahydrate (Ceftriaxone sodium).
thiomethyl]3-cephem-4-carboxylic acid (60g) and 1,2,5,6 tetrahydro-2-methyl-3- thio-5,6
dioxo-l,2,4-triazine'(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino acetate (1) (92g) were
suspended in a mixture of THF (450ml) and H2O (250ml) maintained at 0*’ - 5’C under
stirring. Triethylamine (68.7ml) was added in 2-3 hours at 5’C maintaining the pH 7.5 -
8.5. The reaction progress was monitored by HPLC. After the reaction was complete, the
mixture was extracted with ethylacetate (400ml). Sodium-2-ethyihexanoate (55g) was
added to the aqueous solution and acetone (1.0 lit) was added in 1 hour at 10-15*’C to
complete the crystallization. The product was filtered under N2 atmosphere and wet cake
was dissolved in mixture of water and acetone (1:2 by volume), and cooled to -10 to -
15 C. Coloured impurities were separated. The solution was decanted and diluted with
acetone (2500ml) at 18-20*’C. Precipitated solid was filtered under N2 and washed with
acetone (200ml). Dried under vacuum at 40-45’’C to get pure Ceftriaxone sodium,
95g.which was once again crystallized in sterile area in water -acetone (1: 4 by volume)
mixture to get sterile product. (85 g) (yield ‘ 80%)
HPLC (purity): 98-99.5%
Example - III 7-[[(Z)-2-(2-AminothiazoM-*yl)2-methoxyiminolacetamido]-3'[[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-l,2,4-triazin-3-yl)thio]methyl]-3-cephem-4-carboxyllcacid disodium hemiheptahydrate (Ceftriaxone sodium).
7-Amino-3-[[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-l,2,4-tria2in-3yl)thio]methyl]3-cephem-4-carboxylic acid (20.Og) was suspended in dichloromethane (200nil). To this was added hexamethyldisilazane (17.0g) and trimethylsilyl chloride (3.0g). The suspension was refluxed for 2-3 hours to get clear solution. Cooled to O’C and triethylamine (13.6g) was added slowly. At the same temperature, 1,2,5,6 tetrahydro-2-methyl-3- thio-5,6 dioxo-l,2,4-triazine-(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino acetate (I) (20g) was added. The reaction mixture was monitored by HPLC. After completion of reaction, 200ml water was added and pH was adjusted to 7.0. The aqueous layer was separated, charcoal zed and treated with sodium-2-ethylhexanoate (18.5g) in acetone, reaction was proceeded by same method as mentioned in Ex-II to get final sterile ceftriaxone sodium (28.Og)
Example - IV 3-AcetyloxymethyI-7'[(Z)-(2-aminothiazolyl-4-yl)-2-(methoxyimino) acetamido]-3-cephem-4-carboxyIic acid (Cefotaxime sodium).
A mixture of THF (200ml) and water (150ml) was stirred under inert atmosphere. At 0’ - l’C, 7-aminocephalosporanic acid (25.Og) and 1,2,5,6 tetrahydro-2-methyl-3- thio-5,6 dioxo-l,2,4-tria2ine-(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino acetate (I) (39.8g) were added. Triethylamine (10.4g) was slowly added to reaction by maintaining pH 7.5 to 8.5. The reaction was followed by HPLC. After 4-5 hrs., the reaction mixture was extracted by ethylacetate. The aqueous layer is subjected to charcoal (0.125g) treatment. Ethylacetate was added to the filtrate and the solution was acidified with dil. HCl at 10'*C to pH 3.0. The solid separated was filtered, washed with water and ethylacetate and then dried under vacuum at 40-45'*C to get Cefotaxime, 40.9g (yield 98%). The Cefotaxime acid was dissolved in water at pH 6.5 using sodium carbonate. The solution was filtered
through 0.2 micron under aseptic conditions & the product is crystallized by addition of
acetone. Yield = 38 g
Example - V 7-[((Z)-2-(Aminothiazol-4-yl)-2-methoxyimino]acetamino]-3-methoxymethyl-3-cephem-4-carboxylic acid [Cefpodoxirae acid]*
7-Amino-3-methoxymethyl-3-cephem-4-carboxylic acid (24.2g) and 1,2,5,6 tetrahydro-2-
acetate (I). (35g) were suspended in 400ml of THF and water mixture (1:1). At llO’C
Triethylamine (TEA) 9.0gms added to maintain pH 7-8. The reaction was monitored and
proceeded as described in example II. To the separated aq. layer, pH was adjusted to 2.7
using 16-18% sulphuric acid, Shod was cooled to love, filtered and washed with water
(3x50ml) and finally with acetone (20ml) to obtain the Cefpodoxime acid, 37.5g (yield
HPLC (purity) : 98.0%
Example - VI
Sodium -7-[[(Z)-2-(Aminothiazol-4-yl)-2-methoxyimino] acetaniidol-3-(2-
furanylcarbonyl) thiomethyll-3-cephem-4-carboxylate (sterile buffered Ceftiofur sodium)
7-Amino-3-[(2-furanylcarboxyl)thiomethyl]-3-cephem-4-carboxylic acid (30.0g, 88.2 mmol) and 2-mercapto-5-phenyl-1,3,4-oxadiazolyl-(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino acetate (47.7g, 132.0 mmol) are added to a mixture of dichloromethane (400ml) and methanol (15ml) at temperature 0-5’C. Triethylamine (25.0ml) is added to the reaction mixture in 50-60 min. After completion of reaction, the reaction mixture is extracted with water (400ml), The aqueous layer is separated and treated with charcoal (0.500g), Tetrahydrofuran (400ml) and lOOg of sodium chloride is added to this solution followed by addition of (9.2ml) of hydrochloric acid (35%). The mixture is stirred for 10 min and layers are separated. Tetrahydrofuran layer is treated with charcoal and added to another 75ml solution tetrahydrofuran containing 13.5g of sodiLim-2-cthylhe\anoatc under
stirring. To this solution slowly tetrahydrofiiran(550ml) is added at a temperature of 20*’C, white to creamish solid precipitated out in the solution, which is cooled to 0-5 C for 2.Oh. Ceftiofur sodium thus prepared is filtered under inert atmosphere, washed with acetone and dried under vacuum to get 36-38g of ceftiofur sodium with HPLC (purity) of 98.0%.The ceftiofur sodium thus prepared is dissolved in water (350ml). The pH of the solution is adjusted to 7.5 by adding sodium bicarbonate. Potassium dihydrogen phosphate(l-0-1.5g) is added, the solution is filtered through a 0.2 micron filter under sterile condition and subjected to lyophilization to obtain sterile buffered certifier sodium (37-38 g).
1. Novel derivatives of thiazolyl acetic acid represented by formula (I)
wherein, Ri represents H, trityl, CH3, CRaRbC00R2 (Ra and Rb independently of one another represents hydrogen or methyl, R2 is hydrogen or alkyl)
2. A process of preparing thiazol-4'yl acetic acid derivatives represented by formula
wherein, Ri is as shown above, said process comprising the step of condensing thiazol-4-yl acetic acid represented by formula (IV)
wherein, Ri is as shown above, with 1,2,5,6 tetrahdro-2-methyl-5,6 dioxo-l,2,4'triazin-3-thiol of formula (VI^
in the presence of Voltmeter reagent of formula (V) and in an organic solvent
at a temperature in the range of -loc - +30 , to obtain thiazol-4-yl acetic acid derivatives represented by formula (I).
3. The process of claim 2 wherein the organic solvent is selected from the group
comprising dichloromethane, tetrahydrofliran, dioxane, N,N-dimethylformamide,
acetone, acetonitrile, carbon tetrachloride and a mixture thereof.
4. A process of preparing cephalosporin compound of formula (II)
wherein, Ri represents H, trityl, CH3, CRaRbC00R2 (Ra and Rb independently of one another represents hydrogen or methyl and R2 represents H or C|*C4 alkyl), R3 is -CH3, -CH-CH2, -CH2OCH3, -CH2OCOCH3,
R4 is H or a salt or a carboxylic protecting group or an inner salt, said process comprising the step of acylating the compound or formula (III)
wherein, R3 and R4 are as defined above, R$ is H or trimethylsilyl with a compound of formula (I),
in the presence of an organic solvent, an organic base and a salivating agent at a temperature in the range of -loc - +30 , to obtain the compound of formula (II).
5. The process of claim 4 wherein R4 is hydrogen or an alkali metal salt or an firmer sah.
6. The process of claim 4 wherein the compound of formula II is a sin isomer.
7. The process of claim 4 wherein the organic solvent is selected from the group comprising dichloromethane, tetrahydrofuran, dioxane, N,N-dimethylformamide, acetone, acetonitrile, carbon tetrachloride and a mixture thereof
8. The process of claim 4 wherein the organic base is selected from the group comprising triethylamine, diethylamine, tributylamine, pyridine, N-alkylanilines, l,8-diazabicyclo[5.4.2]undec-7-ene,l,5-diazabicyclo [4.3,0] non-S-ene, N-methyl niorpholine and a mixture thereof and the silylating agent of trimethylsilyi,
9. The process of claim 4 wherein R5 is H, the acylation is done in the presence of water and an organic solvent selected from the group consisting of tetrahydrofuran.
N,N-dimethylacetamide, N,N-dimethylformamide, dioxane, acetoniotrile and mixtures thereof.
10. The process of claim 4 wherein R5 is trimethylsilyl, the acylation is achieved by
doing the reaction in an aprotic organic solvent selected from halogenated
hydrocarbon, toluene, alkyl ether, acetonitrile and a mixture thereof.
11. The process of claim 4 wherein said acylation is performed in the presence of an
organic base selected from the group consisting of triethylamine, N-
methylmorpholine, N-ethylpiperidine, N-methylanilines, l,5-diazabicyclo[4.3.0]
non-5-ene, l,4-diazabicyclo[2.2.2]octane, 4-dimethylaminopyridine and mixtures
12. The process of claim 4 wherein Ri is methyl, R3 is (2,5-dihydro-6-hydroxy-2-
methyl-5-oxo-l,2,4-triazin-3-yl)thiomethyl, purification of this compound is
achieved by dissolving the crude product in a mixture of water and water miscible
organic solvent selected from the group consisting of acetone, isopropyl alcohol,
dioxane and a mixture thereof
13. The process of claim 4 wherein R\ is methyl, R3 is (2,5-dihydro-6'hydroxy-2-
methyl-5-oxo-l,2,4-triazin-3-yl)thiomethyl, the colour impurities are separated at a
temperature ranging between and precipitation is effected by water
miscible organic solvent selected from the group consisting of acetone,
isopropyl alcohol, dioxane and a mixture thereof.
14. Novel derivatives of thiazolyl acetic acid substantially as herein described and
|Indian Patent Application Number||61/MAS/2002|
|PG Journal Number||52/2007|
|Date of Filing||24-Jan-2002|
|Name of Patentee||M/S. ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED|
|Applicant Address||1, 6TH FLOOR, CROWN COURT, 34, CATHEDRAL ROAD, CHENNAI 600 086|
|PCT International Classification Number||C07D 417/12|
|PCT International Application Number||N/A|
|PCT International Filing date|